We conducted imputation to the 1000 Genomes Project of four genome-wide association studies of lung cancer in populations of European ancestry (11,348 cases and 15,861 controls) and genotyped an additional 10,246 cases and 38,295 controls for follow-up. We identified large-effect genome-wide associations for squamous lung cancer with the rare variants BRCA2 p.Lys3326X (rs11571833, odds ratio (OR) = 2.47, P = 4.74 × 10 −20 ) and CHEK2 p.Ile157Thr (rs17879961, OR = 0.38, P = 1.27 × 10 −13 ). We also showed an association between common variation at 3q28 (TP63, rs13314271, OR = 1.13, P = 7.22 × 10 −10 ) and lung adenocarcinoma that had been previously reported only in Asians. These findings provide further evidence for inherited genetic susceptibility to lung cancer and its biological basis. Additionally, our analysis demonstrates that imputation can identify rare disease-causing variants with substantive effects on cancer risk from preexisting genome-wide association study data.
l e t t e r s
We conducted imputation to the 1000 Genomes Project of four genome-wide association studies of lung cancer in populations of European ancestry (11,348 cases and 15,861 controls) and genotyped an additional 10,246 cases and 38,295 controls for follow-up. We identified large-effect genome-wide associations for squamous lung cancer with the rare variants BRCA2 p.Lys3326X (rs11571833, odds ratio (OR) = 2.47, P = 4.74 × 10 −20 ) and CHEK2 p.Ile157Thr (rs17879961, OR = 0.38, P = 1.27 × 10 −13 ). We also showed an association between common variation at 3q28 (TP63, rs13314271, OR = 1.13, P = 7.22 × 10 −10 ) and lung adenocarcinoma that had been previously reported only in Asians. These findings provide further evidence for inherited genetic susceptibility to lung cancer and its biological basis. Additionally, our analysis demonstrates that imputation can identify rare disease-causing variants with substantive effects on cancer risk from preexisting genome-wide association study data.
Lung cancer causes over 1 million deaths each year worldwide 1 . Although primarily caused by tobacco smoking, studies have also implicated inherited genetic factors in the etiology of lung cancer; notably, genome-wide association studies (GWAS) in Europeans have consistently identified polymorphic variation at 15q25.1 (CHRNA5-CHRNA3-CHRNB4), 5p15.33 (TERT-CLPTM1) and 6p21.33 (BAG6 (also called BAT3)-MSH5) as determinants of lung cancer risk [2] [3] [4] [5] [6] . Additionally, susceptibility loci for lung cancer at 3q28, 6q22.2, 13q12.12, 10q25.2 and 22q12.2 in Asians have been identified through GWAS [7] [8] [9] .
Non-small cell lung cancer (NSCLC) is the most common lung cancer histology, comprised primarily of adenocarcinoma (AD) and squamous cell carcinoma (SQ). These lung cancer histologies have different molecular characteristics that reflect differences in etiology and carcinogenesis 10 . Perhaps not surprisingly, there is variability in the genetic effects on lung cancer risk by histology, with subtype-specific associations at 5p15.33 (TERT-CLPTM1) for AD 11, 12 and at 9p21 (CDKN2A/CDKN2B) 13 and 12q13.33 (RAD52) 14 for SQ. In addition, the 6p21.33 associations are stronger for SQ than for AD 13 .
To identify additional lung cancer susceptibility loci, we conducted a meta-analysis of four lung cancer GWAS in populations of European ancestry: the MD Anderson Cancer Center (MDACC) GWAS, the Institute of Cancer Research (ICR) GWAS, the National Cancer Institute (NCI) GWAS and the International Agency for Research on Cancer (IARC) GWAS (Online Methods), which were genotyped using Illumina HumanHap 317, 317+240S, 370Duo, 550, 610 or 1M arrays ( Supplementary Table 1 ). After filtering, the studies provided genotypes on 11,348 cases and 15,861 controls ( Supplementary Table 1 ). Before undertaking meta-analysis of the GWAS data, we searched for potential errors and biases in the data sets. Quantile-quantile (Q-Q) plots of genome-wide association test statistics showed minimal inflation, Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer l e t t e r s rendering substantial cryptic population substructure or differential genotype calling between cases and controls unlikely (λ = 1.01-1.05; Supplementary Fig. 1 ). To bring genotype data obtained from different arrays into a common platform and recover untyped genotypes, we imputed >10 million SNPs using 1000 Genomes Project data as the reference. Q-Q plots for all SNPs and those restricted to rare SNPs (minor allele frequency (MAF) <1%) after imputation did not show evidence of substantive overdispersion introduced by imputation (λ = 0.99-1.06 and λ = 0.82-1.05, respectively; Supplementary Fig. 1 ).
Pooling data from each GWAS, we derived joint ORs and 95% confidence intervals (CIs) under a fixed-effects model for each SNP and the associated per-allele P values. To explore variability in associations according to tumor histology, we derived ORs for all lung cancer, AD and SQ.
Our meta-analysis identified 50 SNPs that showed evidence of association with lung cancer, AD or SQ (P < 5.0 × 10 −6 ; Fig. 1 ) at loci not reported previously in Europeans ( Fig. 1) . We evaluated 1-Mb regions encompassing these 50 SNPs for association through in silico replication in the Harvard 15 and deCODE 16 series. Nine of the SNPs within these 50 regions showed support for an association (combined P < 5.0 × 10 −7 ). We attempted genotyping of these nine SNPs in four additional series: the Heidelberg-European Prospective Investigation into Cancer and Nutrition (EPIC), ICR, IARC and Toronto replications ( Supplementary Table 2b and Online Methods). rs185577307 could not be genotyped because of repetitive sequence. Collectively, genotypes were available from 21,594 cases and 54,156 controls, providing 80% power to detect a variant with MAF of 0.01 and conferring a relative risk of ≥1.5. In the combined analysis of all GWAS plus replication series data, SNPs mapping to 13q13.1 (rs11571833 and rs56084662), 22q12.1 (rs17879961) and 3q28 (rs13314271) showed evidence for association, which was statistically significant after adjustment for multiple testing (P < 3.0 × 10 −9 ; Fig. 2 and Supplementary Table 3 ). We confirmed the high fidelity of imputation by genotyping rs11571833, rs17879961 and rs13314271 in subsets of the ICR, IARC, NCI and MDACC GWAS (Supplementary Table 2 and Online Methods). The NCI GWAS comprised samples from Finland, Italy and the United States. The IARC GWAS comprised samples from ten series from western and eastern Europe and the United States. Although adjustment of test statistics for principal components generated on common SNPs had been applied to these GWAS, confounding of rare variants in spatially structured populations is not necessarily corrected by such methods 17 . We therefore investigated whether country of origin had an impact on the associations at 13q13.1 and 22q12.1; the associations remained statistically highly significant (P < 5.0 × 10 −8 ; Supplementary Table 4 ).
rs11571833 and rs56084662, localizing to 13q13.1 near or within BRCA2, are rare (MAF < 0.01), map 103 kb apart (32,972,376 bp and 32,869,614 bp, respectively) and are moderately correlated (r 2 = 0.45 and D′ = 0.82 based on genotypes from the Heidelberg-EPIC, IARC, ICR and Toronto replication series; Fig. 3 ). rs11571833 (c.9976A>T) is responsible for BRCA2 p.Lys3326X, whereas rs56084662 is located in the 3′ UTR of FRY. Although the association provided by rs11571833 was substantially stronger than that provided by rs56084662 in the combined analysis (OR = 1.83, P = 2.11 × 10 −19 and P = 1.88 × 10 −15 , respectively), a conditional analysis based on directly genotyped samples in the replication series was consistent with the two SNPs tagging the same haplotype. The association at rs11571833 is driven primarily by a relationship with SQ histology rather than AD histology (OR = 2.47, P = 4.74 × 10 −20 and OR = 1.47, P = 4.66 × 10 −4 , respectively; Fig. 2 and Supplementary Table 3 ). A stronger role for BRCA2 in SQ etiology than in AD etiology is reflected in the higher observed mutational frequency in the respective lung cancers (~6% and 1% (refs. 18,19) ). Thr9976 was recently shown to confer a 1.26-fold increased breast cancer risk 20 and has been suggested previously as a risk factor for esophageal and pancreatic cancers 21, 22 . We found no evidence for an association between Thr9976 and lung cancer risk in nonsmokers using directly genotyped samples ( Supplementary Table 2 ); however, these cases comprised <10% of each cohort, and therefore our power to demonstrate a relationship was limited. Previous analyses of families carrying highly penetrant BRCA2 mutations have found either no evidence for any excess risk or a reduced risk of lung cancer in carriers 23, 24 . A possible explanation for these observations is that members of the families studied tended to smoke less than the general population 24 .
The RAD51-BRCA2 interaction is pivotal for BRCA2-mediated double strand-break repair, and exon 27 of BRCA2 encodes one of the highly conserved RAD51 binding domains: homozygous deletion of exon 27 in mice confers susceptibility to tumors, including lung cancer 25 . Thr9976 leads to the loss of the C-terminal domain of BRCA2, inviting speculation that the SNP is functional. Although the deleted region is distal to the RAD51 binding domain and an impact on nuclear localization is unknown 26, 27 , the nearby BRCA2 p.Thr3387Ala alteration interrupts CHK2 phosphorylation and abrogates BRCA2-CHK2-RAD51-mediated recombination repair 28 . Alternatively, the association might be a consequence of linkage disequilibrium (LD) with another BRCA2 mutation. Studies of families with breast cancer of northern European ancestry show that the BRCA2 c.6275delTT and c.4889C>G mutations, which are highly Shown are the genome-wide P values (two sided) obtained using the Cochran-Armitage trend test from analysis of 8.9 million successfully imputed autosomal SNPs in 11,348 cases and 15,861 controls from the discovery phase. The red and blue horizontal lines represent the significance thresholds of P = 5.0 × 10 −8 and P = 5.0 × 10 −6 , respectively. Any region that contained at least one association signal better than P = 5.0 × 10 −6 was selected for the in silico replication.
npg l e t t e r s penetrant for breast and ovarian cancer, originated on a p.Lys3326X haplotype 29 . To gain further insight into a probable genetic basis of the 13q13.1 lung cancer association, we sequenced germline DNA from 70 individuals with lung cancer who carried c.9976A>T from the UK Genetic Lung Cancer Predisposition Study for the c.6275delTT and c.4889C>G mutations; we did not find c.6275delTT or c.4889C>G in any of these individuals. Similarly, sequencing the coding region of BRCA2 identified no clearly pathogenic mutations among 13 individuals from the 1958 British Birth Cohort (58BC), 11 individuals with lung cancer from IARC or 24 individuals with lung cancer carrying Thr9976 from TCGA. In Iceland, Thr9976 is not correlated with the founder BRCA2 mutation resulting in p.256_257del (c.999del5), which greatly increases the risk of breast and ovarian cancer. Paradoxically, whereas Thr9976 is a risk factor for lung cancer, in this population this SNP is not associated with risk of breast or ovarian cancer (Supplementary l e t t e r s have failed to demonstrate that p.Lys3326X affects DNA repair 30 , our findings raise the possibility that p.Lys3326X may have a direct effect on lung cancer risk. The fact that somatic mutation of BRCA2 is not associated with p.Lys3326X carrier status 19 ( Supplementary  Table 6a ) suggests that any impact the SNP has on lung cancer risk is mediated through alternative mechanisms. The relationship at 22q12.1 between the rs17879961 (c.470T>C) and SQ in the combined series (OR = 0.38, P = 1.27 × 10 −13 ) validates an association that has been reported previously 31, 32 (Fig. 2 and Supplementary Tables 3 and 4) . The frequency of rs17879961 varies markedly between populations: it has a MAF of ~5% in eastern Europeans (for example, individuals in the IARC series) but is almost monomorphic in most northern Europeans. This likely accounts for the failure to demonstrate a significant relationship in the ICR, MDACC, Toronto and deCODE series, which comprise largely western European populations ( Fig. 2 and Supplementary Table 3 ). rs17879961 is responsible for the missense mutation in CHEK2 resulting in p.Ile157Thr; CHEK2 is a cell cycle-control gene encoding a pluripotent kinase that can cause arrest or apoptosis in response to DNA damage. Acquired mutation of CHEK2 is rarely seen in lung cancer, and the CHEK2 p.Ile157Thr alteration does not appear to correlate with mutation ( Supplementary Table 6a ), raising the possibility that carrier status per se influences cancer risk. The p.Ile157Thr substitution lies in a functionally important domain of CHEK2 and causes reduced or abolished binding of principal substrates. Although Cys470 increases breast cancer risk 33 , here Cys470 was associated with reduced lung cancer risk. A mechanism for the paradoxical associations is not immediately apparent. However, CHEK2 can have opposite effects on damaged stem cells, retarding stem cell division until DNA damage is repaired or activating apoptosis if damage cannot be repaired. Although speculative, in the presence of continued DNA damage to squamous epithelia by tobacco smoke, the normal stem cell defenses involving CHEK2 might be attenuated by a reduction in CHEK2 activity as a result of p.Ile151Thr 31 . Concordant with such a model is our observation of a paradoxically increased lung cancer risk in nonsmokers (P = 0.05) and in correlated subgroups of AD and women, although this increase was based on small numbers (Supplementary Table 2 ).
The association between variation at 3q28 marked by rs13314271 and lung cancer risk was restricted to AD (OR = 1.13, P = 7.22 × 10 −10 ; Fig. 2 and Supplementary Table 3 ). rs13314271 maps within intron 1 of TP63 (Fig. 3) . Variation at TP63 defined by the intron 1 SNP rs4488809, which is in complete LD with rs13314271 (r 2 = 1.00, D′ = 1.00), is associated with AD in Asians 8 . Our findings provide robust evidence for the generalizability of a relationship between 3q28 variation and AD. We found a weak association between rs13314271 and lung cancer risk in nonsmokers (P = 0.03; Supplementary  Table 2b ). TP63 is a member of the tumor suppressor TP53 gene family, which is pivotal in cellular differentiation and responsiveness to cellular stress 34, 35 . Exposure of cells to DNA damage leads to induction of TP63, and both isoforms have the ability to transactivate TP53 target genes, thereby affecting cellular responsiveness to DNA damage 36 . Although rs13314271 does not map to an evolutionary conserved region, rs7636839, which is correlated with rs13314271 and rs4488809 (r 2 = 1.0), does map to an evolutionarily conserved region and has predicted enhancer activity ( Supplementary Table 6b ). Moreover, rs4488809 has been shown to be an expression quantitative trait locus for TP63 in lung tissue 37 . Although the mechanism by which 3q28 variation affects AD development is unknown, accumulation of DNA damage and a lack of response to genotoxic stress are recognized to contribute to lung carcinogenesis; hence, loss of repair fidelity as a consequence of differential TP63 expression is likely deleterious.
There was no association between rs11571833, rs17879961 and rs13314271 genotypes and cigarette consumption on the basis of smoking information on 43,693 Icelandic subjects ( Supplementary Table 7) , which is in contrast to the association of 15q25 and risk of lung cancer.
Although there is some overlap, distinct DNA lesions are ostensibly repaired by different DNA repair pathways. Histology-specific relationships seen implicate the BRCA2-CHEK2-RAD52 double strand-break repair and homologous recombination pathways as a determinant of SQ and defective TP53 and TERT apoptosistelomerase regulation as a basis of AD risk. npg l e t t e r s
In conclusion, our findings provide further evidence for inherited genetic susceptibility to lung cancer and underscore the importance of searching for histology-specific risk variants. Our data also provide an important proof of principle that 1000 Genomes imputation can be used to detect new, low-frequency, large-effect associations, thereby extending the utility of preexisting GWAS data. Notably, this study facilitated the identification of BRCA2 Thr9976, which is the strongest genetic association in lung cancer reported so far. For a smoker carrying this variant (2% of the population), the risk of developing lung cancer is approximately doubled, which may have implications for identifying high-risk ever-smoking subjects for lung cancer screening. Additionally, future study of the effects of PARP inhibition in smokers with lung cancer carrying BRCA2 Thr9976 may be warranted. 
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ONLINE METHOds
Studies. The study was conducted under the auspices of the Transdisciplinary Research In Cancer of the Lung (TRICL) Research Team, which is a part of the Genetic Associations and MEchanisms in ONcology (GAME-ON) consortium and is associated with the International Lung Cancer Consortium (ILCCO). Tumors from patients were classified as AD, SQ, large-cell carcinoma (LCC), mixed adenosquamous carcinoma (MADSQ) and other NSCLC histologies following either the International Classification of Diseases for Oncology (ICD-O) or WHO coding. Tumors with overlapping histologies were classified as mixed.
Ethics. All participants provided informed written consent. All studies were reviewed and approved by institutional ethics review committees at the involved institutions.
GWAS.
The meta-analysis was based on data from four previously reported lung cancer GWAS of European populations: the MDACC GWAS 3 , the ICR GWAS 6 , the NCI GWAS 13 and the IARC GWAS 2 . In each of the studies, SNP genotyping had been performed using Illumina HumanHap 317, 317+240S, 370, 550, 610 or 1M arrays (Supplementary Table 1) .
IARC GWAS. The IARC GWAS 2 comprised 3,062 lung cancer cases and 4,455 controls derived from five case-control studies: (i) the Carotene and Retinol Efficacy Trial (CARET) cohort 38 ; (ii) the Central Europe multicenter hospitalbased case-control study 39, 40 ; (iii) the hospital-based case-control study from France 40 ; (iv) the hospital-based case-control lung cancer study from Estonia 41, 42 ; and (v) the population-based HUNT2/Tromsø IV lung cancer studies 43 . Patient and control DNAs were derived from EDTA-venous blood samples. The patients with lung cancer were classified according to ICD-O-3: SQ: 8070/3, 8071/3, 8072/3, 8074/3; AD: 8140/3, 8250/3, 8260/3, 8310/3, 8480/3, 8560/3, 8251/3, 8490/3, 8570/3, 8574/3; with tumors with overlapping histologies being classified as mixed. After applying standardized quality-control procedures, 2,533 cases and 3,791 controls were included in the current analysis ( Supplementary Table 1 (refs. 12,47) and tumor histology was abstracted from Certified Tumor Registrars and coded using WHO ICD-O-2 and ICD-O-3. In this study, quality assurance was done by reabstracting 10% of all cancer diagnoses per year. After initial data quality control, the NCI GWAS included 5,739 cases and 5,848 controls; however, an additional 26 cases and 112 controls were excluded because of changes in case status and further quality-control filtering. The current meta-analysis included 5,713 lung cancer cases and 5,736 controls from the NCI GWAS (Supplementary Table 1) .
ICR GWAS. The ICR GWAS comprised 1,952 cases (1,166 male; mean age at diagnosis 57 years, s.d. 6 years) with pathologically confirmed lung cancer ascertained through the Genetic Lung Cancer Predisposition Study (GELCAPS) conducted between March 1999 and July 2004 (ref. 48 ). All cases were British residents and were self-reported to be of European ancestry. To ensure that data and samples were collected from bona fide lung cancer cases and avoid issues of bias from survivorship, only incident cases with histologically or cytologically (if not AD) confirmed primary disease were ascertained. Tumors from patients were classified according to ICD-O3: specifically, SQ: 8070/3, 8071/3, 8072/3, 8074/3; AD: 8140/3, 8250/3, 8260/3, 8310/3, 8480/3, 8560/3, 8251/3, 8490/3, 8570/3, 8574/3; with tumors with overlapping histologies being classified as mixed. Patient DNA was derived from EDTA-venous blood samples using conventional methodologies. Genotype frequencies were compared with publicly accessible data generated by the UK Wellcome Trust Case-Control Consortium 2 (WTCCC2) study 49 of individuals from the 1958 British Birth Cohort (58BC), and blood service was typed using Illumina Human1.2M-Duo Custom_v1 Array BeadChips.
MDACC GWAS. Cases and controls were ascertained from a case-control study at the University of Texas MD Anderson Cancer Center conducted between 1997 and 2007 (ref. 3) . Cases were newly diagnosed patients with histologically confirmed lung cancer presenting at MD Anderson Cancer who had not previously received treatment other than surgery. Clinical and pathological data were abstracted from patient medical records, and lung cancer histology was coded according to the major histological groups. Specifically, as per ICD-O-2, these groups were SQ: 8070/3; AD: 8140/3, 8250/3, 8260/3, 8310/3, 8480/3, 8251/3, 8490/3. Only patients with predominantly or wholly AD or SQ cancers were included; those with mixed histology or unspecified lung cancers were excluded from the study. Controls were healthy individuals seen for routine care at Kelsey-Seybold clinics in the Houston metropolitan area. Controls were frequency matched to cases according to smoking behavior, age in 5-year categories, ethnicity and sex. Former smoking controls were further frequency matched to former smoking cases according to the number of years since smoking cessation (in 5-year categories). After applying quality controls, data were available on 1,150 cases and 1,134 controls.
Quality control of GWAS data sets. Standard quality control was performed on all scans, excluding individuals with low call rate (<90%) and extremely high or low heterozygosity (P < 1.0 × 10 −4 ), as well as all individuals evaluated to be of non-European ancestry (using the HapMap version 2 CEU, JPT/CHB and YRI populations as a reference; Supplementary Table 1 ). For apparent first-degree relative pairs, we removed the control from a case-control pair; otherwise, we excluded the individual with the lower call rate.
Replication series. To validate promising associations from the metaanalysis, we made use of in silico data and imputed genotypes from Harvard and deCODE GWAS data sets together with data from the direct-genotyping Heidelberg-EPIC, ICR, IARC and Toronto replication series.
Harvard. For the Harvard Lung Cancer Susceptibility Study, details of participant recruitment have been described previously 50 . Replication was based on data derived from 1,000 cases and 1,000 controls genotyped using Illumina HumanHap610-Quad arrays. Cases were patients aged >18 years with newly diagnosed, histologically confirmed primary NSCLC. Controls were healthy non-blood related family members and friends of patients with cancer or with cardiothoracic conditions undergoing surgery. The histological classification of lung tumors was performed by two staff pulmonary pathologists at Massachusetts General Hospital according to ICD-O-3: specifically, AD: 8140/3, 8250/3, 8260/3, 8310/3, 8480/3 8560/3; LCC: 8012/3, 8031/3; SQ: 8070/3, 8071/3, 8072/3, 8074/3; other NSCLC: 8010/3, 8020/3, 8021/3, 8032/3, 8230/3. Unqualified samples were excluded if they fit the following quality-control criteria: (i) overall genotype completion rates <95%; (ii) gender discrepancies; (iii) unexpected duplicates or probable relatives (based on a pairwise identity-by-state value of PI_HAT in PLINK >0.185); (iv) heterozygosity rates >6 times the s.d. from the mean; or (v) individuals evaluated to be of non-European ancestry (using HapMap release 23 including the JPT, CEPH, CEU and YRI populations as a reference). Unqualified SNPs were excluded when they fit the following quality-control criteria: (i) SNPs were not mapped on autosomes; (ii) SNPs had a call rate <95% in all GWAS samples; (iii) SNPs had MAF <0.01; or (iv) the genotype distributions of SNPs deviated from those expected by Hardy-Weinberg equilibrium npg integrated release 3, March 2012) as reference using IMPUTE2 v2. Table 1 ). Genotypes were aligned to the positive strand in both imputation and genotyping. Imputation was conducted separately for each scan in which each GWAS data set was pruned to a common set of SNPs between cases and controls before imputation. As previously described, we set thresholds for imputation quality to retain both potential common and rare variants for validation 13, 60 . Specifically, poorly imputed SNPs defined by an RSQR < 0.30 with MaCH or an information measure Is < 0.40 with IMPUTE2 were excluded from the analyses. Tests of association between imputed SNPs and lung cancer were performed under a probabilistic dosage model in SNPTEST v2.5 (ref. 61) , ProbABEL 62 , MaCH2dat v.124 (ref. 58) or the glm function in R. Principle components generated using common SNPs were included in the analysis to limit the effects of cryptic population stratification that might cause inflation of test statistics. The association between each SNP and lung cancer risk was assessed by Cochran-Armitage trend test. The adequacy of the case-control matching and possibility of differential genotyping of cases and controls were formally evaluated using Q-Q plots of test statistics. Meta-analysis was undertaken using inverse-variance approaches. The inflation factor λ was based on the 90% least-significant directly typed SNPs 63 . ORs and associated 95% CIs were calculated by unconditional logistic regression using R (v2.6), Stata v.10 (State College, Texas, US) and PLINK 64 (v1.06) software. Cochran's Q statistic to test for heterogeneity and the I 2 statistic to quantify the proportion of the total variation due to heterogeneity were calculated 65 . I 2 values ≥75% are considered to be characteristic of large heterogeneity 65 . Additionally, analyses stratified by histology, sex, age and smoking status (current, former or never) were performed. All statistical tests were two sided.
The fidelity of imputation as assessed by the concordance between imputed and directly genotyped SNPs was examined in a subset of samples from the UK GWAS, MDACC GWAS, IARC GWAS and NCI GWAS discovery series (Supplementary Table 2 ).
LD metrics were calculated in PLINK using 1000 Genomes data and plotted using SNAP 66 . LD blocks were defined on the basis of HapMap recombination rate (cM/Mb) as defined using the Oxford recombination hotspots and on the basis of the distribution of CIs defined by Gabriel et al. 67 .
Relationship between genotypes and smoking. To examine the relationship between rs11571833 (BRCA2 p.Lys3326X), rs17879961 (CHEK2 p.Ile157Thr) and rs13314271 (TP63) genotype and cigarette consumption (cigarettes per day) 68 , we used data on 43,693 Icelandic subjects (including 34,850 chip-typed individuals).
Sequence analysis of BRCA2 in constitutional DNA. At the ICR, targeted sequencing for the BRCA2 mutations c.6275delTT and c.4889C>G was performed by Sanger implemented on an ABI3700 analyzer (Applied Biosystems; primer sequences and conditions are available on request). Mutational analysis of the complete coding region of BRCA2 was based on exome sequencing data generated using Illumina TruSeq capture technology (Illumina, Inc, San Diego, USA). Analysis of Illumina HiSeq2000 (Illumina, Inc, San Diego, USA) sequence data was performed using an in-house pipeline based on the GATK tool kit.
At IARC, Qiagen Generead (SABiosciences/Qiagen Hilde, Germany) was used to amplify the coding region of BRCA2 in rs11571833 heterozygotes. After library preparation (New England BioLabs, Ipswich, MA, USA), sequencing was performed using an IonTorrent PGM desktop sequencer (Life Technologies, Guilford, San Francisco, CA). Genotypes were called using Ionsuite software. Sequence changes were referenced to the Leiden Open Variation Database (LOVD2) and the BReast CAncer IARC database.
Analysis of TCGA data. The exomes of 243 individuals with lung SQ and 338 individuals with lung AD in TCGA (Project Number #3230) were analyzed at IARC using an in-house pipeline based on the GATK tool set. Variant calls were annotated using ANNOVAR, making use of use the National Heart, Lung, and Blood Institute's Exome Sequencing Project and 1000 Genomes data.
Copy number variation. Copy number variation was assessed from Human SNP Array 6.0 data. We retrieved level 3 TCGA data comprising normalized log 2 ratios of the fluorescence intensities between the target sample and a reference sample. We included only tumor-normal paired data in our analysis. We considered a log 2 ratio ≤0.5 as reflecting loss and a log 2 ratio >0.5 as reflecting gain. Annotation was performed by adding the genes contained in each of the remaining segments using EnsEMBL databases.
